TG Therapeutics FY2025 EPS Estimate Raised by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at HC Wainwright raised their FY2025 earnings estimates for shares of TG Therapeutics in a report issued on Wednesday, January 15th. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will post earnings per share of $1.26 for the year, up from their prior estimate of $1.17. HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.17 per share.

Other equities analysts also recently issued research reports about the stock. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. TD Cowen assumed coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. Finally, The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Up 1.5 %

Shares of TG Therapeutics stock opened at $30.18 on Thursday. TG Therapeutics has a 52-week low of $12.84 and a 52-week high of $36.84. The company has a 50 day moving average of $31.63 and a 200 day moving average of $25.60. The company has a market capitalization of $4.70 billion, a P/E ratio of -301.77 and a beta of 2.24. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter last year, the firm posted $0.73 EPS. The company’s revenue for the quarter was down 49.4% on a year-over-year basis.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Brookstone Capital Management lifted its position in shares of TG Therapeutics by 3.7% in the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 624 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after buying an additional 270,286 shares during the period. Principal Financial Group Inc. boosted its position in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in TG Therapeutics by 3.8% in the 3rd quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company’s stock worth $2,945,000 after acquiring an additional 4,756 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 26,358 shares of company stock valued at $781,497. Corporate insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.